We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2018

Published: July 2018
Pages: 77
Code: 42706DB8CD6E3B8D163487AA9B87EC2F
Format: PDF
Publisher Global Markets Direct
From Add to basket
$ 3,500.00
Smoothened Homolog (Protein Gx or SMO) - Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.
Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 3, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Genetic Disorders, Gastrointestinal, Infectious Disease and Undisclosed which include indications Medulloblastoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Basal Cell Carcinoma (Basal Cell Epithelioma), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gorlin Syndrome (Basal Cell Nevus Syndrome), Peritoneal Cancer, Aspergillosis, Blastomycosis, Cirrhosis, Colon Cancer, Esophageal Cancer, Glioblastoma Multiforme (GBM), Histoplasmosis, Leukemias, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Small-Cell Lung Cancer.
The latest report , outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Additonal Information

  • - The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
  • - The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • - The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects
  • - The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • - The report summarizes all the dormant and discontinued pipeline projects
  • - The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

Companies Mentioned

BeiGene Ltd
Genentech Inc
Ignyta Inc
IMPACT Therapeutics Inc
Mayne Pharma Group Ltd
Pfizer Inc
Sun Pharma Advanced Research Company Ltd

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO) Identify the use of drugs for target identification and drug repurposing Identify potential new clients or partners in the target demographic Develop strategic initiatives by understanding the focus areas of leading companies Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Add to basket
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Smoothened Homolog (Protein Gx or SMO) - Overview
  • Smoothened Homolog (Protein Gx or SMO) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development
  • BeiGene Ltd
  • Genentech Inc
  • Ignyta Inc
  • IMPACT Therapeutics Inc
  • Mayne Pharma Group Ltd
  • Pfizer Inc
  • Sun Pharma Advanced Research Company Ltd
  • Smoothened Homolog (Protein Gx or SMO) - Drug Profiles
  • glasdegib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSA-10 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IMP-5471 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • itraconazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • patidegib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Smoothened Homolog for Medulloblastoma and Colon Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Target SMO and HDAC for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize Smoothened (Smo) Receptor for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Smoothened Homolog for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sonidegib phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • taladegib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vismodegib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Smoothened Homolog (Protein Gx or SMO) - Dormant Products
  • Smoothened Homolog (Protein Gx or SMO) - Discontinued Products
  • Smoothened Homolog (Protein Gx or SMO) - Product Development Milestones
  • Featured News & Press Releases
  • Jun 27, 2018: U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia
  • Jun 05, 2018: HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway
  • May 21, 2018: HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
  • May 14, 2018: HedgePath Pharmaceuticals Announces Expanded Patent Coverage
  • May 02, 2018: Mayne Pharma Announces FDA Acceptance of New Drug Application for Its Antifungal Suba-Itraconazole Capsule
  • Jan 11, 2018: HedgePath Pharmaceuticals Receives Orphan Drug Designation for SUBA-Itraconazole from the European Medicines Agency
  • Nov 20, 2017: FDA Grants Breakthrough Therapy Designation and Orphan Drug Designation to Pellepharm for Topical Patidegib in Gorlin Syndrome
  • Oct 30, 2017: HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update
  • Sep 20, 2017: Sun Pharma Odomzo New Label Approval Shows Sustained Duration of Response of 26 Months in Treatment of Locally Advanced Basal Cell Carcinoma
  • Jul 31, 2017: PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas
  • Jul 25, 2017: HedgePath Pharmaceuticals Receives Clarity From FDA Regarding Pathway to Potential Regulatory Submission
  • May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update
  • Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome
  • Dec 03, 2016: New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
  • Nov 28, 2016: Curis Announces Full Approval of Roche’s Erivedge® in the European Union
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
  • List of Tables
  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indications, H2 2018
  • Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Companies, H2 2018 (Contd..2), H2 2018
  • Number of Products under Investigation by Universities/Institutes, H2 2018
  • Products under Investigation by Universities/Institutes, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by BeiGene Ltd, H2 2018
  • Pipeline by Genentech Inc, H2 2018
  • Pipeline by Ignyta Inc, H2 2018
  • Pipeline by IMPACT Therapeutics Inc, H2 2018
  • Pipeline by Mayne Pharma Group Ltd, H2 2018
  • Pipeline by Pfizer Inc, H2 2018
  • Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018
  • Dormant Products, H2 2018
  • Dormant Products, H2 2018 (Contd..1), H2 2018
  • Dormant Products, H2 2018 (Contd..2), H2 2018
  • Discontinued Products, H2 2018
  • List of Figures
  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018

Keywords
;